

UNITED STATES DISTRICT COURT FOR THE  
DISTRICT OF NEW HAMPSHIRE

Marine Polymer, Inc.

v.

Civil No. 06-cv-100-JD  
Opinion No. 2010 DNH 026

HemCon, Inc.

O R D E R

HemCon, Inc. filed an assented-to motion to file a reply to Marine Polymer, Inc.'s objection to HemCon's motion for discovery at the same time that the court issued its order denying the motion for discovery. HemCon filed its motion within the time allowed to provide notice of an intent to file a motion for leave to file a reply, which was extended by the holiday, on Monday, February 15. See LR 7.1(e)(2). Because of the proximity of pretrial deadlines, the court issued the order on the motion without waiting the last few hours of the time allowed for notice. Therefore, the motion for leave is granted, and the court will reconsider the order in light of HemCon's reply.<sup>1</sup>

---

<sup>1</sup>Because a motion for leave to file a surreply would only be granted in extraordinary circumstances, the court will not wait the additional time allocated for that procedure. See LR 7.1(e)(3).

I. Vascular Solutions Case

In the order denying HemCon's motion for discovery, the court concluded that HemCon's argument that it had been misled about the subjects of litigation in Vascular Solutions, Inc. v. Marine Polymer Techs., Inc., 590 F.3d 56 (1st Cir. 2009), was not persuasive and did not provide a basis for reopening discovery. HemCon contends in its reply that the public filings in Vascular Solutions did not provide notice of the parties' exchange of evidence pertaining to market share and suitable noninfringing substitute products in that case. HemCon also argues that although the Vascular Solutions case was mentioned in a deposition in this case, that inquiry did not uncover evidence of market share and substitute products.

HemCon reiterates in its reply that it had propounded interrogatories to Marine Polymer asking for documents concerning any evaluation of market share of chitin or chitosan products and "documents concerning any civil action or proceeding based in whole or in part on any chitin product or chitosan product manufactured, advertised, or sold by [Marine Polymer]." HemCon believes that Marine Polymer failed to produce documents from the Vascular Solutions case that are within the documents requested by HemCon's interrogatories in this case.

As the court noted in the order denying HemCon's discovery motion, HemCon does not seek sanctions for discovery abuses under Federal Rule of Civil Procedure 37(c). Instead, HemCon asked the court to exercise its discretion to allow additional discovery related to the Vascular Solutions case and a submission Marine Polymer made to the FDA.

Federal Rule of Civil Procedure 26(e) remains in effect and requires Marine Polymer to supplement its disclosures. If Marine Polymer has materials from the Vascular Solutions case that are responsive to HemCon's interrogatories, those documents must be disclosed immediately. HemCon has not shown, however, that additional discovery is necessary, which would require another delay in the trial schedule.

## II. FDA Submission

In support of its motion for additional discovery, HemCon asserted that Marine Polymer's recent disclosure of its submission to the FDA of a comparison of its SYVEK product to a collagen product was untimely and had led to HemCon's discovery of a related European patent. HemCon argued that the information about the European patent "would have inevitably led to further depositions" regarding the scope and content of prior art, Marine Polymer's knowledge of prior art, and Marine Polymer's intent in

not disclosing material prior art. The court concluded that HemCon's vague references to inevitable further depositions was insufficient to justify reopening discovery at this late stage of the case.

In its reply, HemCon argues that Marine Polymer's defense, that the European patent claiming a bandage for the rapid cure of wounds was irrelevant to the '245 patent claims, is "disingenuous" because wound healing is mentioned in the specification of the '245 patent. As was explained in the claim construction order, the '245 patent shares a long and complex specification section with a family of related patents that claim a variety of other inventions. For that reason, the specification, confusingly, includes descriptions and information about inventions that are not claimed by the '245 patent. Therefore, despite references to wound healing in the '245 patent, HemCon has not persuaded the court that the newly-discovered European patent is sufficiently pertinent to this case to justify reopening discovery.

Conclusion

For the foregoing reasons, the defendant's motion for leave to file a reply (document no. 183) is granted. The court has considered the reply. The order denying the defendant's motion to reopen discovery stands.

SO ORDERED.

  
\_\_\_\_\_  
Joseph A. DiClerico, Jr.  
United States District Judge

February 17, 2010

cc: Julie M. Baher, Esquire  
Garet K. Galster, Esquire  
Daniel R. Johnson, Esquire  
Heather E. Krans, Esquire  
Joseph A. Kromholz, Esquire  
Lynda Q. Nguyen, Esquire  
Brian M. Poissant, Esquire  
Daniel D. Ryan, Esquire  
Ognian V. Shentov, Esquire  
Jonathan M. Shirley, Esquire  
Daniel E. Will, Esquire  
Leigh S. Willey, Esquire